Russia's sovereign wealth fund, the Russian Direct Investment Fund (RDIF) on Wednesday said it expects to start supplying Sputnik V vaccine against COVID-19 to India in November this year.
Sputnik V, a vaccine against coronavirus, has been developed by the Gamaleya National Research Center of Epidemiology and Microbiology and RDIF.
In a interview to CNBC-TV18’s Shereen Bhan, Kirill Dmitriev, chief executive officer, said it has submitted all necessary documents to Indian regulator and will share the cost of trials 50:50 with pharma giant Dr Reddy's Laboratories.
Earlier, the Russian Direct Investment Fund has collaborated with Dr Reddy's Laboratories to conduct clinical trials of the Sputnik V vaccine against COVID-19 as well as its distribution.
Dmitriev said RDIF is taking the financial risk of starting to produce the vaccine before the approval and has already started the technology transfer to Dr Reddy's.
He said RDIF has a strategic partnership with Dr Reddy's, not just for the production but will also partner pharma company to distribute the vaccine In other markets too.
"There will be separate agreements for different countries. We have already sold our vaccine subject to regulatory approvals to Mexico, Brazil. We have more than 30 countries interested in buying more than 1.2 billion doses right now. We will be announcing additional agreements with other countries shortly," Dmitriev said.
He further added, "We are in good discussions with Covax, Gavi, WHO. We will be joining and applying to join the Covax facility because we believe it is very important that different countries have access to different vaccines. I think this approach of having different vaccines is the right one."